A review of the use of latanoprost for glaucoma since its launch

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 5, 2012, Pages 723-745

  Digiuni, Maurizio ^a   Fogagnolo, Paolo ^b   Rossetti, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Latanoprost; Medical therapy; Ocular hypertension; Primary open angle glaucoma; Review

Indexed keywords

ACETAZOLAMIDE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BROMOCRIPTINE; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; PERGOLIDE; PILOCARPINE; TIMOLOL; TRAVOPROST; UNOPROSTONE;

ADJUVANT THERAPY; APNEA; ARTICLE; ASTHMA; BRONCHOSPASM; CLOSED ANGLE GLAUCOMA; CONJUNCTIVAL HYPEREMIA; CORNEA PERMEABILITY; DERMATITIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; GLAUCOMA; HERPES SIMPLEX KERATITIS; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; INFLUENZA; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; MEDLINE; MIGRAINE; MUSCULOSKELETAL PAIN; OPEN ANGLE GLAUCOMA; RETINA MACULA CYSTOID EDEMA; RETINA PIGMENT EPITHELIOPATHY; SKIN ALLERGY; TACHYCARDIA; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION;

ANTIHYPERTENSIVE AGENTS; GLAUCOMA; HUMANS; PROSTAGLANDINS F, SYNTHETIC;

EID: 84858690387     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.662219     Document Type: Article

References (238)

1. Alward WL. Medical management of glaucoma. N Engl J Med 1998;29339(18):1298-307 (Pubitemid 28496198)
2. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989;15:107(2):186-8 (Pubitemid 19049847)
3. Chung HS, Harris A, EVans DW, et al. Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv Ophthalmol 1999;43(Suppl 1):S43-50 (Pubitemid 29328578)
4. Perry CM, Mc Gavin JK, Culy CR, Ibbotson T. Latanoprost. An update of its use in glaucoma and ocular hypertension. Drugs Aging 2003;20:597-630 (Pubitemid 36808230)
5. Aquino MV, Lat-Luna M. The effect of latanoprost vs. timolol on intraocular pressure in patients with glaucoma and ocular hypertension. Asian J Ophthalmol 1999;1:3-7
6. Leonard R. Statistics on Vision Impairment: A Resource Manual. In: Leonard RArlene R. editor; 5th edition. Gordon Research Institute of Lighthouse International; New York, USA: 2002
7. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd edition. Editrice DOGMA S.r.l; Savona, Italy: 2008
8. Rossetti L, Goni F, Denis P, et al. Focusing on glaucoma progression and the clinical importance of progression rate measurement: A review. Eye (Lond) 2010;24(Suppl 1):S1-7
9. Hoyng PFJ, Van Beek LM. Pharmacological therapy for glaucoma. A review. Drugs 2000;59:411-34
10. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-16
11. Bucci MG; The Italian Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: A randomized, observer-masked multicenter study in patients with open-angle glaucoma. J Glaucoma 1999;8:24-30
12. Weinreb RN. Compliance with medical treatment of glaucoma. J Glaucoma 1992;1:134-6
13. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233-6
14. Pfizer, Inc.: Xalatan (Latanoprost) Package Insert. Pfizer, Inc; New York, NY, USA: 2003
15. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008;115(5):790-5
16. Nilsson SFE, Samuelsson M, Bill A, et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2, -l-isopropylesterin the cynomolgus monkey. Exp Eye Res 1989;48:707-16 (Pubitemid 19143452)
17. Gabelt BT, Kaufman PL. Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989;49:389-402 (Pubitemid 19239397)
18. Toris CB, Yablonski ME, Wang Y-L, et al. Prostaglandin A2increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res 1995;61:649-57 (Pubitemid 26017011)
19. Toris CB, Camras CB, Yablonski ME. EffectsofPhXA41, a new prostaglandin Fk analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304 (Pubitemid 23274021)
20. Toris CB, Camras CB, Yablonski ME, et al. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous harrier function. Surv Ophthalmol 1997;41:S69-75 (Pubitemid 27154527)
21. Stjernschantz J, SeEn G, Ocklind A, et al. Effects of latanoprost and related prostaglandin analogues. In: A lm A, Weinreb R, editors. Uveoscleral Outflow. Mosby-Wolfe; London: 1998. p. 57-72
22. Poyer JF, Millar C, Kaufman PL, Prostaglandin F. Effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol 1995;36:2461-5
23. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandin action on ciliary smooth muscle extracellularmatrix metabolism: Implications for uveoscleral outflow. Surv Ophthalmol 1997;41:S53-9 (Pubitemid 27154525)
24. Lindsey JD, Weinreb RN. Effects of prostaglandins on uveoscleral outflow. In: A h A, Weinreb R, editors. Uveoscleral Outflow. Mosby-Wolfe; London: 1998. p. 41-55
25. Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol 2003;48(Suppl 1):S17-20 (Pubitemid 41126691)
26. Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002;47(Suppl 1):S6-S12 (Pubitemid 35232215)
27. Sjoquist B, Ryding P, Stjernschantz J. The systemic pharmacokinetics of latanoprost in man after intravenous and topical administration. Paper Presented at ARVO; May 1994; Florida
28. Bito LZ, Baroody RA. The ocular pharmacokinetics of eicosanoids and their derivatives. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester. Exp Eye Res 1987;44(2):217-26 (Pubitemid 17060567)
29. Sjoquist B, Johasson A. The ocular pharmacokinetics of latanoprost, new antiglaucoma drug, studied by autoradiography. Invest Ophthalmol Vis Sci 1995;36(4):5823
30. AlVan G, Calissendorff B, Scideman P, et al. Absorption of ocular timolol. Clin Pharmacokinet 1980;5:95
31. Basu S, Sjoquist B, Stjernschantz J, et al. Corneal permeability and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids 1994;50:161-8 (Pubitemid 24110315)
32. Calissendorff B, Sjoquist B, Hogberg G, Grunge-Lowerud A. Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther 2002;18:127-31 (Pubitemid 34297296)
33. Higginbotham EJ, Diestelhorst M, Pfeiffer N, et al. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol 2002;47(Suppl 1):S133-40 (Pubitemid 35232227)
34. Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996;9(5):363-78 (Pubitemid 26388160)
35. Diestelhorst M, Krieglstein GK, Lusky M, Nagasubramanian S. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analog. Surv Ophthalmol 1997;41(Suppl 2):S77-81 (Pubitemid 27154528)
36. Fristrom B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol 1993;111(5):662-5 (Pubitemid 23143176)
37. Xalatan: Latanoprost ophthalmic solution [package insert]. New York: Pfizer and Upjohn Co.; 2009. Available from: uspi-xalatan-multi.pdf
38. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102(12):1743-52 (Pubitemid 26004426)
39. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103(1):126-37 (Pubitemid 26046169)
40. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103(1):138-47 (Pubitemid 26046170)
41. Aung T, Chew PT, Yip CC, et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 2001;131(5):636-42 (Pubitemid 32422122)
42. Kimal Arici M, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol 1998;22(1):37-42 (Pubitemid 29083234)
43. Rulo AH, Greve EL, Hoyng PF. Additive ocular hypotensive effect of latanoprost and acetazolamide. A shortterm study in patients with elevated intraocular pressure. Ophthalmology 1997;104(9):1503-7 (Pubitemid 28116820)
44. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv Ophthalmol 2001;45(Suppl 4):S353-60
45. Gandolfi S, Simmons ST, Sturm R, Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18(3):110-21 (Pubitemid 32852703)
46. Konstas AG, Maltezos AC, Gandi S, et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 1999;128(1):15-20 (Pubitemid 29315758)
47. Larsson LI. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology 2001;108(8):1439-44
48. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41(9):2566-73 (Pubitemid 30624384)
49. Bron AM, Denis P, Nordmann JP, et al. Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol. Acta Ophthalmol Scand 2001;79(3):289-93 (Pubitemid 32577316)
50. Netland PA, Landry T, SulliVan EK, Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132(4):472-84 (Pubitemid 32904567)
51. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: A meta-analysis of randomized controlled clinical trials. J Glaucoma 2008;17(8):667-73
52. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703 (Pubitemid 36457976)
53. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63 (Pubitemid 36020425)
54. Walters TR, DuBiner HB, Carpenter SP, et al. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: A 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004;49(Suppl 1):S26-35 (Pubitemid 38324612)
55. Cantor LB, Hoop JS, Morgan L, et al. Intraocular pressure- lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006;90:1370-3 (Pubitemid 44702062)
56. Cantor LB, WuDunn D, Cortes A, et al. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004;49(Suppl 1):S12-18 (Pubitemid 38317483)
57. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008;115(7):1117-22
58. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology 2005;112(7):1177-85 (Pubitemid 40916921)
59. Zhang WY, Po AL, Dua HS, Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2001;85:983-90 (Pubitemid 32706175)
60. Einarson TR, Kulin NA, Tingey D, Iskedjian M. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clin Ther 2000;22:1502-15 (Pubitemid 32056088)
61. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114(8):929-32 (Pubitemid 26271456)
62. Suzuki M, Mishima HK, Masuda K, et al. Efficacy and safety of latanoprost eye drops for glaucoma treatment: A 1-year study in Japan. Jpn J Ophthalmol 2000;44(1):33-8 (Pubitemid 30029132)
63. Alm A, Widengard I. Latanoprost: Experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 2000;78(1):71-6 (Pubitemid 30095316)
64. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998;105(1):82-7 (Pubitemid 28070605)
65. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996;103(11):1916-24 (Pubitemid 26403748)
66. Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006;113(2):239-46 (Pubitemid 43170772)
67. Racz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996;114:268-73 (Pubitemid 26086731)
68. Mishima HK, Kiuchi Y, Takamatsu M, et al. Circadian intraocular pressure management with latanoprost: Diurnal and nocturnal intraocular pressure reduction and increased uveo- scleral outflow. Surv Ophthalmol 1997;41:S139-44 (Pubitemid 27154538)
69. Larsson L, Mishima HK, Takamatsu M, et al. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol 2002;47:S90-6 (Pubitemid 35232222)
70. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005;112:262-6 (Pubitemid 40202562)
71. Cheng JW, Wei RL. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther 2008;30(4):622-32
72. Susanna R Jr, Giampani J Jr, Borges AS, et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001;108(2):259-63 (Pubitemid 32115953)
73. Saito M, Takano R, Shirato S. Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma. Am J Ophthalmol 2001;132(4):485-9 (Pubitemid 32904568)
74. Jampel HD, Bacharach J, Sheu WP, Latanoprost/Unoprostone Study Group. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol 2002;134(6):863-71 (Pubitemid 35425455)
75. Kampik A, Arias-Puente A, O'Brart DP, Vuori ML; European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: A randomized observer-masked multicenter study. J Glaucoma 2002;11(2):90-6 (Pubitemid 34298588)
76. Stewart WC, Day DG, Stewart JA, et al. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;131(5):631-5 (Pubitemid 32422121)
77. DuBiner HB, Mroz M, Shapiro AM, Dirks MS; Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther 2001;23(12):1969-83 (Pubitemid 34073189)
78. Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3- month randomised study. Graefes Arch Clin Exp Ophthalmol 2000;238(1):19-23
79. Garcia Sanchez J. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension-a three-month randomised study. Spanish Latanoprost Study Group. Eur J Ophthalmol 2000;10(3):198-204
80. Polo V, Larrosa JM, Gomez ML, et al. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol Scand 2001;79(1):6-9 (Pubitemid 32061025)
81. Honrubia FM, Larsson LI, Spiegel D; European Latanoprost Study Group. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 2002;80(6):635-41 (Pubitemid 36024478)
82. Nordmann JP, Soderstrom M, Rouland JF, Malecaze F. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group. Br J Ophthalmol 2000;84(2):181-5 (Pubitemid 30251663)
83. Pillunat LE, Larsson LI; European and Canadian Latanoprost Study Group. Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma. Br J Ophthalmol 2003;87(12):1492-6 (Pubitemid 38010555)
84. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97
85. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13 (Pubitemid 34620348)
86. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 2000;130:832-3 (Pubitemid 32000869)
87. Hollo G, Chiselita D, Petkova N, et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006;16:816-23 (Pubitemid 46174396)
88. Hommer A, Kapik B, Shams N; The Unoprostone Adjunctive Therapy Study Group. Unoprostone as adjunctive therapy to timolol: A double masked randomised study versus brimonidine and dorzolamide. Br J Ophthalmol 2003;87:592-8 (Pubitemid 36535333)
89. Strahlman ER, Vogel R, Tipping R, Clineschmidt CM. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. Ophthalmology 1996;103:1283-93 (Pubitemid 26282513)
90. Lee PY, Shao H, Camras CB, Podos SM. Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology 1991;98:1079-82
91. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, A prostaglandin F2 alpha analogue and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899-902
92. Miglior S, Grunden JW, Kwok K; Xalacom/Cosopt European Study Group. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/ timolol in open-angle glaucoma or ocular hypertension. Eye (Lond) 2010;24(7):1234-42
93. Pfeiffer N; European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240(11):893-9 (Pubitemid 36097111)
94. Shin DH, Feldman RM, Sheu WP; Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004;111(2):276-82 (Pubitemid 38183227)
95. Higginbotham EJ, Feldman R, Stiles M, Dubiner H; Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs. monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120(7):915-22 (Pubitemid 34755544)
96. Simmons ST, Earl ML; Alphagan/Xalatan Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: Tolerance and peak intraocular pressure lowering. Ophthalmology 2002;109(2):307-14 (Pubitemid 34106036)
97. Diestelhorst M. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t. i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group. Graefes Arch Clin Exp Ophthalmol 2000;238(5):433-9 (Pubitemid 30342664)
98. Petounis A, Mylopoulos N, Kandarakis A, et al. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: A randomized, open-label, multicenter study in Greece. J Glaucoma 2001;10(4):316-24 (Pubitemid 32781348)
99. Widengard I, Maepea O, Alm A. Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol 1998;82(4):404-6 (Pubitemid 28177151)
100. Toris CB, Zhan GL, Zhao J, et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol 2001;131(6):722-8 (Pubitemid 32522640)
101. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open- label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 2004;122:957-65 (Pubitemid 39037958)
102. O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133(6):836-7 (Pubitemid 34580639)
103. Simmons ST, Samuelson TW. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group. Clin Ther 2000;22(4):388-99 (Pubitemid 30304791)
104. Susanna R Jr, Nicolela MT, Oga E. Additive effect of latanoprost to the combination of timolol and dorzolamide. J Glaucoma 2000;9(2):183-6 (Pubitemid 32441330)
105. Shin DH, McCracken MS, Bendel RE, et al. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy. Ophthalmology 1999;106(2):386-90 (Pubitemid 30191642)
106. Patelska B, Greenfield DS, Liebmann JM, et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol 1997;124(3):279-86 (Pubitemid 27386669)
107. Ikeda Y, Mori K, Ishibashi T, et al. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol 2006;50(2):153-7
108. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol 2002;47(Suppl 1):S77-89 (Pubitemid 35232221)
109. Choplin N, Bernstein P, Batoosingh AL, et al. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol 2004;49(Suppl 1):S19-25 (Pubitemid 38317484)
110. Rossetti L, Gandolfi S, Traverso C, et al. An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma 2006;15(3):238-43
111. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95-104 (Pubitemid 30439106)
112. Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther 2002;18:287-91 (Pubitemid 34701304)
113. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 2002;19:275-81 (Pubitemid 36249775)
114. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;110:609-14 (Pubitemid 36262750)
115. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2002;47:295
116. Konstas AG, Hollo G, Irkec M, et al. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: A crossover, observer-masked, three-centre study. Br J Ophthalmol 2007;91(6):757-60 (Pubitemid 46846646)
117. Camras CB, Hedman K. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma 2003;12:466-9 (Pubitemid 37494173)
118. Gaton DD, Sagara T, Lindsey JD, et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin (2 alpha)-isopropyl ester treatment. Arch Ophthalmol 2001;119:1165-70 (Pubitemid 32730004)
119. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997;38:2772-80 (Pubitemid 28009399)
120. Weinreb R, Toris C, Gabelt B, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002;47:S53-64 (Pubitemid 35232219)
121. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998;67:179-91 (Pubitemid 28428266)
122. Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2 treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999;117:794-801 (Pubitemid 29265042)
123. Camras CB, Schumer RA, Marsk A, et al. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol 1992;110:1733-8
124. Nagasubramanian S, Sheth GP, Hitchings RA, et al. Intraocular pressurereducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 1993;100:1305-11 (Pubitemid 23274022)
125. Camras CB, Siebold EC, Lustgarten JS, et al. Maintained reduction of intraocular pressure by prostaglandin F2-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 1989;96:1329-37 (Pubitemid 19231761)
126. Aung T, Wong HT, Yip CC, et al. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: A preliminary study. Ophthalmology 2000;107(6):1178-83
127. Chew PT, Exact Study Group. The Efficacy of Xalatan in Angle Closure Glaucoma Therapy (EXACT) Study. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO). Annual Meeting 2001 April 29 - May 4
128. Hung PT, Hsieh JW, Chen YF, Wei T. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy. J Ocul Pharmacol Ther 2000;16(1):43-7 (Pubitemid 30069124)
129. McKibbin M, Menage MJ. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye 1999;13:31-4 (Pubitemid 29121594)
130. Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal tension glaucoma. Am J Ophthalmol 1998;125(6):585-92 (Pubitemid 28268887)
131. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103(8):1276-82 (Pubitemid 26282512)
132. Greve EL, Rulo AH, Drance SM, et al. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: A review of short-term studies with three dose regimens of latanoprost treatment. Surv Ophthalmol 1997;41(Suppl 2):S89-92 (Pubitemid 27154530)
133. Konstas AG, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 2007;114(4):653-7 (Pubitemid 46483692)
134. Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999;106(3):550-5 (Pubitemid 30191591)
135. Vetrugno M, Maino A, Quaranta GM, Cardia L. A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy. Eur J Ophthalmol 2000;10(3):205-11
136. Scherer WJ, Hauber FA. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma. J Glaucoma 2000;9(2):179-82 (Pubitemid 32441329)
137. Altuna JC, Greenfield DS, Wand M, et al. Latanoprost in glaucoma associated with Sturge-Weber syndrome: Benefits and side-effects. J Glaucoma 1999;8(3):199-203 (Pubitemid 32435880)
138. Yang CB, Freedman SF, Myers JS, et al. Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome. Am J Ophthalmol 1998;126(4):600-2 (Pubitemid 28475930)
139. Konstas AG, Lake S, Economou AI, et al. 24-hour control with a latanoprost-timolol fixed combination vs. timolol alone. Arch Ophthalmol 2006;124:1553-7 (Pubitemid 44748727)
140. Law SK, Song BJ, Fang E, et al. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. Ophthalmology 2005;112:2123-30 (Pubitemid 41720990)
141. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding af-finities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501-15 (Pubitemid 38030237)
142. Susanna R Jr, Medeiros FA. The pros and cons of different prostanoids in the medical management of glaucoma. Curr Opin Ophthalmol 2001;12(2):149-56 (Pubitemid 32232088)
143. Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 2007;6:45-52 (Pubitemid 46150523)
144. Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 2003;19:23-35 (Pubitemid 36249877)
145. Stewart WC, Kolkler AE, Stewart JA, et al. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003;135:314-20 (Pubitemid 36279517)
146. Stjernschantz JW. From PGF (2 alpha)- isopropylester to latanoprost: A review of the development of xalatan: The Proctor lecture. Invest Ophthalmol Vis Sci 2001;42:1134-45 (Pubitemid 32381949)
147. Honrubia F, Garcia-Sanchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogs in patients with ocular hypertension or glaucoma: A meta-analysis of randomised clinical trials. Br J Ophthalmol 2009;93(3):316-21
148. Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogs in patients with pseudophakia and aphakia. Arch Ophthalmol 2005;123:186-92 (Pubitemid 40189705)
149. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41(Suppl 2):S129-38 (Pubitemid 27154537)
150. Grierson I, Lee WR, Albert DM. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol 1999;117(3):394-6 (Pubitemid 29133740)
151. Smith-Thomas L, Moustafa M, Spada CS, et al. Latanoprost-induced pigmentation in human iridial melanocytes is fibroblast dependent. Exp Eye Res 2004;78(5):973-85 (Pubitemid 38402205)
152. Demitsu T, Manabe M, Harima N, et al. Hypertrichosis induced by latanoprost. J Am Acad Dermatol 2001;44(4):721-3
153. Chiba T, Kashiwagi K, Kogure S, et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma 2001;10(5):406-10 (Pubitemid 33062657)
154. Latanoprost-Induced Iris Pigmentation Study Group. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes. Jpn J Ophthalmol 2006;50(2):96-9
155. Hara T. Increased iris pigmentation after use of latanoprost in Japanese brown eyes. Nippon Ganka Gakkai Zasshi (J Jpn Oph- thalmol Soc) 2001;105:314-21
156. Chiba T, Kashiwagi K, Ishijima K, et al. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol 2004;48:141-7 (Pubitemid 38453787)
157. Tsai JC, Sivak-Callcott JA, Haik BG, et al. Latanoprost-induced iris heterochromia and open-angle glaucoma: A clinicopathologic report. J Glaucoma 2001;10:411-13 (Pubitemid 33062658)
158. Albert DM, Gangnon RE, Zimbric ML, et al. A study of iridec- tomy histopathologic features of latanoprostand non-latanoprost- treated patients. Arch Ophthalmol 2004;122:1680-5 (Pubitemid 39473414)
159. Grierson I, Jonsson M, Cracknell K. Latanoprost and pigmentation. Jpn J Ophthalmol 2004;48:602-12 (Pubitemid 40104633)
160. Arranz-Marquez E, Teus MA, Saornil MA, et al. Analysis of irises with a latanoprost-induced change in iris color. Am J Ophthalmol 2004;138:625-30 (Pubitemid 39420492)
161. Krohn J, Hove VK. Iris cyst associated with topical administration of latanoprost. Am J Ophthalmol 1999;127:91-3 (Pubitemid 29036626)
162. Browning DJ, Perkins SL, Lark KK. Iris cyst secondary to latanoprost mimicking iris melanoma. Am J Ophthalmol 2003;135:419-21 (Pubitemid 36279546)
163. Lai IC, Kuo MT, Teng LMC. Iris pigment epithelial cyst induced by topical administration of latanoprost. Br J Ophthalmol 2003;87:366 (Pubitemid 36313003)
164. Gentile RC, Leibmann JM, Tello C, et al. Ciliary body enlargement and cyst formation in uveitis. Br J Ophthalmol 1996;80:895-9 (Pubitemid 26366557)
165. Gupta V, Rao A, Sinha A, Kumar N. Post-traumatic inclusion cysts of the iris: A longterm perspective series. Acta Ophthalmol Scand 2007;85:893-6 (Pubitemid 350142816)
166. Sodhi PK. Iris cyst secondary to latanoprost mimicking iris melanoma. Am J Ophthalmol 2003;136:780
167. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002;47(Suppl 1):S185-202 (Pubitemid 35232233)
168. Burnett JW, Harvey VM. Circumscribed palmar or plantar hypokeratosis: Report of two additional cases. J Am Acad Dermatol 2004;51:843-4 (Pubitemid 39516915)
169. Johnstone MA. Hypertrichosis and increased pigmentation of eye- lashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 2001;132(4):472-84
170. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997;115(9):1206-8 (Pubitemid 27387964)
171. Shaikh MY, Bodla AA. Hypertrichosis of the eyelashes from pros- taglandin analog use: A blessing or a bother to the patient? J Ocul Pharmacol Ther 2006;22(1):76-7 (Pubitemid 43364084)
172. Demitsu T, Manabe M, Harima N, et al. Hypertrichosis induced by latanoprost. J Am Acad Dermatol 2001;44(4):721-3
173. Inouye K, Wakakura M, Inoue J, et al. Adverse reaction after use of latanoprost in Japanese glaucoma patients. Nippon Ganka Gakkai Zasshi 2006;110:581-7
174. Elgin U, Batman A, Becker N, Iihan B. The comparison of eyelash lengthening effect of latanoprost therapy in adults and children. Eur J Ophthalmol 2006;16:247-50 (Pubitemid 43874395)
175. Reynolds A, Murray PI, Colloby PS. Darkening of eyelashes in a patient treated with latanoprost. Eye 1998;12:741-3 (Pubitemid 28418589)
176. Johnstone MA. Hypertrichosis and increased pigmentation of eye- lashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-7 (Pubitemid 27425878)
177. Strober BE, Potash S, Grossman ME. Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis 2001;67:109-10 (Pubitemid 33756241)
178. Brandt JD, VanDenburgh AM, Chen K, et al. Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial. Ophthalmology 2001;108:1023-31 (Pubitemid 32500015)
179. Food and Drug Administration, Division of Anti-infective and Ophthalmology Products Advisory Committee. Briefing information: Bimatoprost ophthalmic solution for the treatment of hypotrichosis of the eyelashes. Available from: ac/08/briefing/2008-4397b1-03-FDA.pdf [Accessed 30 September 2011]
180. O'Toole L, Cahill M, O'Brien C. Eyelid hypertrichosis associated with latanoprost is reversible. Eur J Ophthalmol 2001;11:377-9.70 (Pubitemid 34160718)
181. Chen CS, Wells J, Craig JE. Topical prostaglandin F2 analog induced poliosis. Am J Ophthalmol 2004;137:965-6 (Pubitemid 38582066)
182. Wand M, Ritch R, Isbey EK Jr, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol 2001;119:614-15 (Pubitemid 32293569)
183. Kook MS, Lee K. Increased eyelid pigmentation associated with use of latanoprost. Am J Ophthalmol 2000;129:804-6 (Pubitemid 30604165)
184. Herndon LW, Williams RD, Wand M, Asrani S. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol 2003;135:713-15 (Pubitemid 36457983)
185. Abdel-Malek ZA, Swope VB, Amornsiripanitch N, Nordlund JJ. In vitro modulation of proliferation and melanization of S91 melanoma cells by prostaglandins. Cancer Res 1987;47:3141-6 (Pubitemid 17082638)
186. Woodward DR, Regan JW, Lake S, Ocklind A. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol 1997;41:S15-21 (Pubitemid 27154520)
187. Imesch PD, Wallow IHL, Albert DM. The color of the human eye. A review of morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol 1997;41:S117-23 (Pubitemid 27154535)
188. Jimbow K. Formation, chemical compositions and functions of melanin pigments in mammals. In: Matoltsy AG, editor. Biology of the Integument. Springer Verlag; New York; 1986. p. 278
189. Centofanti M, Oddone F, Chimenti S, et al. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Am J Ophthalmol 2006;142(6):1059-60 (Pubitemid 44853893)
190. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: Is there a causal relation? Curr Opin Ophthalmol 2000;11(2):94-100 (Pubitemid 30164028)
191. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997;41(Suppl 2):S105-10 (Pubitemid 27154533)
192. Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early post-operative pseudophakias. Arch Ophthalmol 1999;117:34-40 (Pubitemid 29056717)
193. Smith SL, Pruitt CA, Sine CS, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999;77(6):668-72 (Pubitemid 30006808)
194. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105(2):263-8 (Pubitemid 28090830)
195. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126(1):37-41 (Pubitemid 28341216)
196. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45 (Pubitemid 12149145)
197. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998;126:602-4 (Pubitemid 28475931)
198. Camras CB, Bhuyan KC, Podos M, et al. Multiple dosing of prostaglandin F2a or epinephrine on cynomolgus monkey eyes: II. Slit-lamp biomicroscopy, aqueous humor analysis, and fluorescein angiography. Invest Ophthalmol Vis Sci 1987;28:921-6 (Pubitemid 17074940)
199. Yousufazi SY, Abdel-Latif AA. Prostaglandin F2a and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res 1996;63:305-10 (Pubitemid 26325120)
200. Sacca S, Pascotto A, Siniscalchi C, Rolando M. Ocular complications of latanoprost in uveitic glaucoma: Three case reports. J Ocul Pharmacol Ther 2001;17(2):107-13 (Pubitemid 32299075)
201. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53(Suppl 1):S93-105
202. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999;127(5):602-4 (Pubitemid 29215774)
203. Ekatomatis P. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br J Ophthalmol 2001;85(8):1008-9 (Pubitemid 32706180)
204. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol 2002;133:401-3 (Pubitemid 34171592)
205. Deai T, Fukuda M, Hibino T, et al. Herpes simplex virus genome quantification in two patients who developed herpetic epithelial keratitis during treatment with antiglaucoma medications. Cornea 2004;23(2):125-8 (Pubitemid 38292705)
206. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999;127:531-6 (Pubitemid 29215763)
207. Kaufman HE, Varnell ED, Toshida H, et al. Effects of topical unoprostone and latanoprost on acute and re- current herpetic keratitis in the rabbit. Am J Ophthalmol 2001;131:643-6 (Pubitemid 32422123)
208. Beam G, Reardon G, Zimmerman TJ. Association between ocular herpes simplex virus and topical ocular hypotensive therapy. J Glaucoma 2004;13:361-4 (Pubitemid 39281575)
209. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 2004;81:574-7 (Pubitemid 39095648)
210. Lee JW, Kim DY, Lee YK. Two cases of deepening of the upper lid sulcus from topical bimatoprost therapy. J Korean Ophthalmol Soc 2007;48:332-6
211. Filippopoulos T, Paula JS, Torun N, et al. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg 2008;24:302-7
212. Tappeiner C, Perren B, Iliev ME, et al. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost- can bimatoprost cause enophthalmos? Klin Monbl Augenheilkd 2008;225:443-5 (Pubitemid 352016479)
213. Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 2009;25:471-2
214. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol 2009;53:176-9
215. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol 2011;55(1):22-7
216. Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol 2011;55(6):600-4
217. Nakakura S, Tabuchi H, Kiuchi Y. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost. Optom Vis Sci 2011;88(9):1140-4
218. Sudesh S, Cohen EJ, Rapuano CJ, Wilson RP. Corneal toxicity associated with latanoprost. Arch Ophthalmol 1999;117(4):539-40 (Pubitemid 29169655)
219. Morales J, Shihab ZM, Brown SM, Hodges MR. Herpes simplex virus dermatitis in patients using latanoprost. Am J Ophthalmol 2001;132(1):114-16 (Pubitemid 32600902)
220. Kozobolis VP, Detorakis ET, Maskaleris G, et al. Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops. Am J Ophthalmol 2005;139(4):742-3
221. Szerenyi K, Sorken K, Garbus JJ, et al. Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol 1994;118:312-15 (Pubitemid 24281723)
222. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994;232:561-5 (Pubitemid 24249226)
223. Xu KP, Yagi Y, Tsubota K. Decrease in corneal sensitivity and change in tear function in dry eye. Cornea 1996;15:235-9 (Pubitemid 26123061)
224. Fraunfelder FT. Extraocular fluid dynamics: how best to apply topical ocular medication. Trans Am Ophthalmol Soc 1976;74:457-87 (Pubitemid 8073156)
225. Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology 1984;91:1361-3 (Pubitemid 15208905)
226. Hedner J, Everts B, Moller CS. Latanoprost and respiratory function in asthmatic patients: Randomized, double-masked, placebo-controlled crossover evaluation. Arch Ophthalmol 1999;117(10):1305-9 (Pubitemid 30029340)
227. Xalatan: Latanoprost ophthalmic solution [package insert]. New York: Pfizer and Upjohn Co.; 2009. Available from: uspi-xalatan-multi.pdf
228. Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002;47(Suppl):S6-12 (Pubitemid 35232215)
229. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: Part I. Clin Pharmacokinet 2002;41:959-98 (Pubitemid 35168438)
230. Anderson GD, Lynn AM. Optimizing pediatric dosing: A developmental pharmacologic approach. Pharmacotherapy 2009;29:680-90
231. Raber S, Courtney R, Maeda-Chubachi T, A6111139 Study Group. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: A phase 1, Open-Label Study. Ophthalmology 2011;118(10):2022-7
232. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000;84(7):710-13 (Pubitemid 30438546)
233. Bull SARAC. Respiratory tract reactions to latanoprost. Swed Adverse Drug React Advisory Committee 1998;67:4-5
234. Mitra M, Chang B, James T. Exacerbation of angina associated with latanoprost. BMJ 2001;323(7316):783
235. No authors listed Cardiovascular disorder due to latanoprost eye drops? Prescr Int 1999;8(41):85
236. Peak AS, Sutton BM. Systemic adverse effects associated with topically applied latanoprost. Ann Pharmacother 1998;32(4):504-5 (Pubitemid 28166620)
237. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol 2001;119(2):300-1
238. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: A systematic classification. J Glaucoma 2003;12:393-8 (Pubitemid 37237370)